Search

Your search keyword '"PAVONE MACALUSO M"' showing total 787 results
Start Over Author "PAVONE MACALUSO M"
787 results on '"PAVONE MACALUSO M"'

22. Clinical and Experimental Projects on Chemotherapy of Bladder Tumours

Author

Pavone-Macaluso, M., Rausa, L., Gebbia, N., Caramia, G., Rizzo, F.P., Arena, E., Tessitore, V., and Vecchioni, M.

Abstract

Our clinical and experimental experience with chemotherapy of bladder tumours is reviewed. The routes of drug administrations, drug dosages and combinations, are presented. Adjuvant radiotherapy and chemoprophylaxis of certain tumours are discussed.S. Afr. Med. J., 48, 631 (1974)

Published
2017

24. Epidemiology of Urolithiasis

Author

Pavone-Macaluso, M., Rotolo, U., Caramia, G., Melloni, D., Zichichi, Antonino, editor, Pavone-Macaluso, Michele, editor, Smith, Philip H., editor, Vercellone, Antonio, editor, Maiorca, Rosario, editor, and Rotolo, Ugo, editor

Published
1981
Full Text
View/download PDF

25. Adjuvant Therapy of T1 Bladder Carcinoma: Preliminary Results of an EORTC Randomized Study

Author

Schulman, C., Sylvester, R., Robinson, M., Smith, P., Lachand, A., Denis, L., Pavone-Macaluso, M., De Pauw, M., Staquet, M., Allfrey, V. G., editor, Allgöwer, M., editor, Berenblum, I., editor, Bergel, F., editor, Bernard, J., editor, Bernhard, W., editor, Blokhin, N. N., editor, Bock, H. E., editor, Braun, W., editor, Bucalossi, P., editor, Chaklin, A. V., editor, Chorazy, M., editor, Cunningham, G. J., editor, Porta, G. Della, editor, Denoix, P., editor, Dulbecco, R., editor, Eagle, H., editor, Eker, R., editor, Good, R. A., editor, Grabar, P., editor, Harris, R. J. C., editor, Hecker, E., editor, Herbeuval, R., editor, Higginson, J., editor, Hueper, W. C., editor, Isliker, H., editor, Kieler, J., editor, Kirsten, W. H., editor, Klein, G., editor, Koprowski, H., editor, Koss, L. G., editor, Martz, G., editor, Mathé, G., editor, Mühlbock, O., editor, Nakahara, W., editor, Old, L. J., editor, Potter, V. R., editor, Sabin, A. B., editor, Sachs, L., editor, Saxén, E. A., editor, Schmidt, C. G., editor, Spiegelman, S., editor, Szybalski, W., editor, Tagnon, H., editor, Taylor, R. M., editor, Tissières, A., editor, Uehlinger, E., editor, Wissler, R. W., editor, Rentchnick, P., editor, Bonadonna, Gianni, editor, Mathé, Georges, editor, and Salmon, Sydney E., editor

Published
1979
Full Text
View/download PDF

28. Environmental factors in superficial bladder cancer. Preliminary report of a prospective study

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, MELLONI, Darvinio, GALLO, Alessia, ALTIERI V, MORGIA G, PAVONE MACALUSO M, DI LALLO A, SAITA A, MOTTA M, SALZANO L, CINDOLO L, ZITO A. A. STUDY FROM GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA, V, ALTIERI, V, MORGIA, G, ALLEGRO, R, PAVONE MACALUSO, M, MELLONI, D, DI LALLO, A, GALLO, A, SAITA, A, MOTTA, M, CINDOLO, L, SALZANO, L, ZITO, A GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, ALTIERI V, MORGIA G, ALLEGRO R, PAVONE-MACALUSO M, MELLONI D, DI LALLO A, GALLO A, SAITA A, MOTTA M, SALZANO L, CINDOLO L, and ZITO A A STUDY FROM GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2004

29. Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC)

Author

Colombo R, Leib Z, Pavone Macaluso M, Engelstein D., SALONIA , ANDREA, Colombo, R, Salonia, Andrea, Leib, Z, Pavone Macaluso, M, and Engelstein, D.

Abstract

What's known on the subject? and What does the study add? Microwave-induced hyperthermia and mitomycin C is a device-assisted approach used to treat non-muscle invasive bladder cancer (NMIBC) either in the adjuvant (prophylactic) set-up or in an ablative regimen. Until recently, around 20 different studies have been published with data on the short term results of treatment. Previous prospective randomized studies showed the superiority of the chemo-hyperthermia regimen when compared to intravesical chemotherapy alone in terms of recurrence-free survival in intermediate and high-risk NMIBC patients at minimum 24-month follow-up. The current study confirmed the result also in long-term (minimum 10 years) follow-up. It also represents one of a few to show such extended follow-up periods for any intravesical therapy for NMIBC. OBJECTIVE center dot To present long-term efficacy data of intravesical thermochemotherapy vs chemotherapy alone with mitomycin-C (MMC) randomly administered to patients with non-muscle-invasive bladder cancer (NMIBC) as an adjuvant treatment after complete transurethral resection. PATIENTS AND METHODS center dot In all, 83 patients with intermediate-/high-risk NMIBC, following complete transurethral resection, were randomly assigned to receive either intravesical thermochemotherapy by means of Synergo (R) (Medical Enterprises, Amsterdam, The Netherlands) or intravesical chemotherapy alone, for prophylaxis of tumour recurrence. center dot Two doses of MMC (20 mg dissolved in 50 mL distilled water administered throughout two consecutive sessions) was used as the chemotherapeutic agent in both arms. center dot In all, 75 patients completed the original study (35 of 42 in the treatment arm, 40 of 41 in the control arm), whose results at minimum 2-year follow-up have already been published. center dot Recently, the files of these patients have been updated for long-term outcome definition. Data on general health, follow-up examinations, tumour relapse or progression, and cause of death were collected and analysed. RESULTS center dot Updated complete data collection was available for 65/75 (87%) of the original patients. center dot The median follow-up for tumour-free patients was 91 months. The 10-year disease-free survival rate for thermochemotherapy and chemotherapy alone were 53% and 15%, respectively (P < 0.001). center dot An intent-to-treat analysis performed to overcome the potential bias introduced by the asymmetrical discontinuation rate still showed a significant advantage of the active treatment over the control treatment. Bladder preservation rates for thermochemotherapy and chemotherapy alone were 86% and 79%, respectively. CONCLUSION center dot This is the first analysis of long-term follow-up of patients treated with intravesical thermochemotherapy. The high rate (53%) of patients who were tumour-free 10 years after treatment completion, as well as the high rate (86%) of bladder preservation, confirms the efficacy of this adjuvant approach for NMIBC at long-term follow-up, even in patients with multiple tumours.

Published
2011

30. Survival risk factors in T1G3 non-muscle-invasive (NMI) bladder cancer consevatively treated. Long term results

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, CORACI, Giuseppe, DI DIO, Michele, MELLONI, Darvinio, RUGGIRELLO A, PAVONE MACALUSO M, ARAGONA F, SERRETTA V, ALLEGRO R, RUGGIRELLO A, CORACI G, DI DIO M, PAVONE-MACALUSO M, ARAGONA F, and MELLONI D

Subjects
bladder cancer, T1G3, conservative treatment, Settore MED/24 - Urologia
Abstract

Introduction: The most relevant risk factor in T1G3 NMI transitional cell carcinoma of the bladder (TCCB) is the presence of Tis. The long term results of conservative management still are a matter of controversy. The role of BCG in preventing progression and death in this category of NMI TCCB is not definitely proved. The published experiences of conservative treatment of high risk TCCB often include unselected patients, small numbers and short follow-up. Immediate radical cystectomy is advocated by many urologists. Objectives: The aim of the study is to identify the survival risk factors in 236 selected patients conservatively treated. Methods: Between January 1976 and December 2005, 236 patients with T1G3 bladder tumors were treated by TUR plus adjuvant intravesical therapy. Patients with previuos T1G3, Tis, more than 3 tumors or greater than 3 cm were excluded. Tumors were primary in 177 (75.3%) and single in 144 (61.5%) cases. Urinary cytology was obtained within 30 days after TUR, the last 51 (21.6%) patients, since 2000, were submitted to re-TUR. A sequential combination of mitomycin C (30mg/30ml) and epirubicin (50mg/50ml) was adopted in 106 patients (44.9%). BCG or other agents were given intravesically in 85 (36.0%) and 38 (16.1%) patients respectively for 12 months. Seven (3%) patients refused intravescical therapy. In the case of Ta-T1 recurrence. TUR and one year of adjuvant intravesical therapy were repeated. Patients went off study if Tis, T1G3 or T-category tumor over T1 were detected. Age, previuos history, number of tumors, time to recurrence, re-TUR, adjuvant therapy, and response to treatment were considered for survival in multivariate analysis. Results: At a mean follow-up period of 52 months (range: 3-246 months), 116 patients (49.2%) recurred. The recurring tumor was T1 in 47 (40.5%) cases and T1G3 in 33 cases (28.4%). In 11 additional patients (9.5%) a Tis was detected. Twenty-five patients (10.6%) progressed and 15 patients (6.4%) underwent cystectomy. Median overall survival was 167 months. Median survival in 195 patients (82.6%) preserving their bladder was 119 months. The 5-year progression-free survival rate was 87.8%. Thirty-two patients (13.6%) died, 22 (9.3%) for bladder cancer.. Recurrence was found significantly lower in single tumors (p=0.012) and in BCG-treated patients (

Published
2008

31. PROSTATA (PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA)

Author

PAVONE MACALUSO M, ABBADESSA, Daniela, SERRETTA, Vincenzo, PAVONE, Carlo, UTET SCIENZE MEDICHE, ED.L.VELLA, PAVONE MACALUSO M, ABBADESSA D, SERRETTA V, and PAVONE C

Subjects
PROSTATITI, IPERTROFIA PROSTATICA, CANCRO DELLA PROSTATA, Settore MED/24 - Urologia
Published
2008

32. Multicentric study comparing intravesical chemotherapy alone and with local microwave hyperthermia for prophylaxis of recurrence of superficial transitional cell carcinoma

Author

Colombo, R, Da Pozzo, L, Salonia, A, Rigatti, P, Leib, Z, Baniel, J, Caldarera, E, Pavone-Macaluso, M, Colombo R, Da Pozzo L, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, Pavone-Macaluso M, Colombo, R, Da Pozzo, L, Salonia, A, Rigatti, P, Leib, Z, Baniel, J, Caldarera, E, Pavone-Macaluso, M, Colombo R, Da Pozzo L, Salonia A, Rigatti P, Leib Z, Baniel J, Caldarera E, and Pavone-Macaluso M

Abstract

Purpose: To compare the efficacy and local toxicity of the intravesical instillation of a cytostatic drug versus the same cytostatic agent in combination with local hyperthermia as an adjuvant treatment, after complete transurethral resection (TURB) of superficial transitional cell carcinoma (TCC) of the bladder. Patients and Methods: The study was designed as a prospective, multicentric, randomized trial. Eighty-three patients suffering from primary or recurrent superficial (Ta-T1) TCC of the bladder, after a complete TURB, were randomly assigned to receive intravesical instillations of mitomycin C (MMC) alone, for 41 patients, and MMC in combination with local microwave-induced hyperthermia, for 42 patients. For the combined approach, a new system, Synergo101–1 (Medical Enterprises, Amsterdam, the Netherlands) was used. The effectiveness evaluation end points of the study were evaluation of recurrence-free survival and the estimated probability of recurrence. The safety evaluation end points included subjective and objective side effects and clinical complications. For the efficacy end point, Kaplan-Meier analysis was employed, with the log-rank test for significance. Minimum follow-up time was 24 months. Results: Of the 83 randomly assigned patients, 75 completed the study according to the protocol and had valid cystoscopy results. Survival analysis of the 75 assessable patients demonstrated a highly significant difference in the survival curves in favor of thermochemotherapy. Subjective intolerance and clinical complications were significantly higher but transient and moderate in the combined treatment group. Conclusion: In our series, endovesical thermochemotherapy appears to be more effective than standard endovesical chemotherapy as an adjuvant treatment for superficial bladder tumors at 24-month follow-up, despite an increased but acceptable local toxicity.

Published
2003

33. Combination of intravesical chemotherapy and hyperthermia for the treatment of superficial bladder cancer: preliminary clinical experience

Author

Colombo, R, Salonia, A, Da Pozzo, L, Naspro, R, Freschi, M, Paroni, R, Pavone-Macaluso, M, Rigatti, P, Colombo R, Salonia A, Da Pozzo L, Naspro R, Freschi M, Paroni R, Pavone-Macaluso M, Rigatti P, Colombo, R, Salonia, A, Da Pozzo, L, Naspro, R, Freschi, M, Paroni, R, Pavone-Macaluso, M, Rigatti, P, Colombo R, Salonia A, Da Pozzo L, Naspro R, Freschi M, Paroni R, Pavone-Macaluso M, and Rigatti P

Abstract

The prevalence of superficial transitional cell carcinoma of the bladder (STCCB) is still increasing in spite of improved adjuvant chemotherapic and/or immunoprophylaxis approaches. Thus, there is certainly an urgent need to improve our ability to control this disease. Local hyperthermia has a therapeutical potential for the treatment of many solid tumors, especially when used in combination with other treatments, such as radiation and chemotherapy. In particular, a synergistic or, at least, supra-additive anti-tumor cell killing effect was documented when local hyperthermia was administered in combination with selected cytostatic drugs. Recently, advances in miniaturized technology have allowed the development of a system specifically designed for delivering an endovesical thermo-chemotherapy regimen in humans. In preliminary clinical experiences, insofar mainly carried out as mono-institutional investigations, the combined treatment using this system was demonstrated to be feasible, minimally invasive and safe when performed on out-patient basis. Moreover, the anti-tumoral efficacy seemed to be significantly enhanced when compared with that obtained using intravesical chemotherapy alone for both adjuvant (prophylaxis) and neo-adjuvant (ablative) approaches to superficial bladder cancer.

Published
2003

34. Fattori di rischio ambientale nel carcinoma vescicale superficiale. Risultati su 577 pazienti sottoposti a chemioterapia endovescicale adiuvante

Author

ALLEGRO, Rosalinda, SERRETTA, Vincenzo, MELLONI, Darvinio, TESTA, Giuseppe, Armenio, Angelo, GALLO, Alessia, ALTIERI, V, MORGIA, G, ANNESE, P, RUGGIRELLO, A, DI LALLO, A, MAGNO, C, CAMMARATA, C, SALZANO, L, SIRAGUSA, A, D'ELIA, A, MOTTA, M, COSENTINO, C, BORRUSO, L, BARTOLOTTA, A, SELVAGGI, FP, FALVO, F, ARAGONA, F, PAVONE MACALUSO, M., ALLEGRO, R, SERRETTA, V, ALTIERI, V, MORGIA, G, ANNESE, P, RUGGIRELLO, A, DI LALLO, A, MELLONI, D, MAGNO, C, TESTA, G, ARMENIO, A, CAMMARATA, C, SALZANO, L, SIRAGUSA, A, D'ELIA, A, MOTTA, M, COSENTINO, C, BORRUSO, L, BARTOLOTTA, A, SELVAGGI, FP, GALLO, A, FALVO, F, ARAGONA, F, and PAVONE-MACALUSO, M

Published
2006

35. ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO E ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC). STUDIO RANDOMIZZATO DI FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU)

Author

SERRETTA, Vincenzo, GALUFFO, Antonino, DISPENSA, Nino, ALLEGRO, Rosalinda, PAVONE, Carlo, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, PAVONE MACALUSO M., SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, GALUFFO A, DISPENSA N, ALLEGRO R, PAVONE C, and PAVONE-MACALUSO M

Published
2006

36. low dose oral chemotherapy for hormone refractory prostate carcnoma.Estramustine phosphate versus estramustine phosphate and etoposide. A randomised phase II study of GSTU Found

Author

SERRETTA, Vincenzo, GALUFFO, Antonino, MELLONI, Darvinio, PAVONE, Carlo, ALLEGRO, Rosalinda, MORGIA G, ALTIERI V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M. DE GRANDE G, PAVONE MACALUSO M, SERRETTA V, MORGIA G, ALTIERI V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M DE GRANDE G, GALUFFO A, MELLONI D, PAVONE C, PAVONE MACALUSO M, and ALLEGRO R

Published
2006

37. ESTRAMUSTINE PHOSPATE VERSUS INTERMITTENT LOW DOSE ORAL COMBINATION OF ESTRAMUSTINE PHOSPATE AND ETOPOSIDE IN HORMONE REFRACTORY PROSTATE CARCINOMA. A PHASE II STUDY OF GSTU FOUND

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, PAVONE, Carlo, MELLONI, Darvinio, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, RUGGIRELLO A, PAVONE MACALUSO M., SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, ALLEGRO R, RUGGIRELLO A, PAVONE C, MELLONI D, and PAVONE-MACALUSO M

Published
2006

39. Water Chlorination and other environmental factors in bladder cancer. Result of a multicentre study

Author

SERRETTA, Vincenzo, ALLEGRO, Rosalinda, MELLONI, Darvinio, TESTA, Giuseppe, ALTIERI V, MORGIA G, CINDOLO L, DI LALLO A, MAGNO C, SALZANO L, MOTTA M, SAITA A, SELVAGGI FP, ANNUNZIATA G, SBLENDORIO D, PAVONE MACALUSO M, GOUC, GSTU, SERRETTA V, ALTIERI V, MORGIA G, CINDOLO L, ALLEGRO R, DI LALLO A, MELLONI D, MAGNO C, SALZANO L, MOTTA M, SAITA A, SELVAGGI FP, ANNUNZIATA G, TESTA G, SBLENDORIO D, PAVONE-MACALUSO M, GOUC, and GSTU

Published
2005

40. Ruolo della terapia di mantenimento e fattori di rischio ambientale nel carcinoma vescicale superficiale. Pazienti sottoposti a chemioterapia endovescicale adiuvante. Risultati preliminari di uno studio randomizzato su 577 pazienti

Author

GALUFFO, Antonino, SERRETTA, Vincenzo, MELLONI, Darvinio, VACCARELLA, Gianpaolo, Armenio, Angelo, ALLEGRO, Rosalinda, ALTIERI V, MORGIA G, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, CACCIATORE M, CAMMARATA C, NICOLOSI D, FALVO F, GANGE E, SIRAGUSA A, ARAGONA F, PAOLA Q, SPAMPINATO A, PAVONE MACALUSO M, MEMBRI DEL GSTU, GALUFFO A, SERRETTA V, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, COSENTINO V, BORRUSO L, MOTTA M, SAITA A, CACCIATORE M, VACCARELLA G, CAMMARATA C, ARMENIO A, NICOLOSI D, FALVO F, GANGE E, SIRAGUSA A, ARAGONA F, PAOLA Q, SPAMPINATO A, ALLEGRO R, PAVONE-MACALUSO M, and MEMBRI DEL GSTU

Published
2005

43. RISULTATI DI UNO STUDIO RANDOMIZZATO SULLA TOSSICITÀ E SUL RUOLO DEL MANTENIMENTO NELLA CHEMIOPROFILASSI ENDOVESCICALE PRECOCE DOPO TUR DI CARCINOMA VESCICALE SUPERFICIALE

Author

ALTIERI V, MORGIA G, MOTTA M, ANNESE P, CARRIERI G, DI LALLO A, SBLENDORIO D, SALZANO L, BROTZA D, RUGGIERO G, SAITA A, CACCIATORE M, SIMONE NS, IADEVAIA M, VACIRCA F, SELVAGGI FP, PIRRITANO D, BIZZINI A, PEPE P, PAVONE MACALUSO M, ALLEGRO R. E. I. MEMBRI DEL GSTU, SERRETTA, Vincenzo, MELLONI, Darvinio, SCUTO, Fabio, ZITO, Anna, GALLO, Alessia, ALTIERI V, SERRETTA V, MORGIA G, MELLONI D, SCUTO F, MOTTA M, ZITO A, ANNESE P, CARRIERI G, DI LALLO A, GALLO A, SBLENDORIO D, SALZANO L, BROTZA D, RUGGIERO G, SAITA A, CACCIATORE M, SIMONE NS, IADEVAIA M, VACIRCA F, SELVAGGI FP, PIRRITANO D, BIZZINI A, PEPE P, PAVONE-MACALUSO M, and ALLEGRO R E I MEMBRI DEL GSTU

Published
2005

44. Chemioterapia domiciliare nel carcinoma prostatico ormonorefrattario (HRPC). Studio di fase II del gruppo studio tumori urologici (GSTU)

Author

SERRETTA, Vincenzo, MELLONI, Darvinio, GALUFFO, Antonino, ALLEGRO, Rosalinda, PARRINELLO, Marica, ALTIERI V, MORGIA G, MAGNO C, SIRAGUSA A, MOTTA M, ORESTANO F, BULGARELLA A, DE GRANDE G, PAVONE MACALUSO M, MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU, SERRETTA V, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, SIRAGUSA A, MOTTA M, ORESTANO F, BULGARELLA A, DE GRANDE G, GALUFFO A, ALLEGRO R, PARRINELLO M, PAVONE-MACALUSO M, and MEMBRI DEL GRUPPO STUDI TUMORI UROLOGICI GSTU

Published
2005

45. Fumo di sigaretta e risorsa idrica in pazienti affetti da carcinoma vescicale superficiale. XV Congresso Nazionale SIUro, Giardini Naxos 3-6 novembre 2005. 1

Author

MORGIA G, ALTIERI V, MOTTA M, MAGNO C, CHINCOLI S, CACCIATORE M, SIMONE NS, CONTINO G, PIRRITANO D, MASALA A, DELIA A, BULGARELLA A, MAZZA R, RICCI BARBINI V, RAGUSO G, ESPOSITO C, CICALESE V, PAVONE MACALUSO M. E. I. MEMBRI DEL GSTU, SERRETTA, Vincenzo, MELLONI, Darvinio, GALUFFO, Antonino, TESTA, Giuseppe, GENTILE, Monica, ALLEGRO, Rosalinda, MORGIA G, SERRETTA V, ALTIERI V, MELLONI D, GALUFFO A, MOTTA M, TESTA G, MAGNO C, CHINCOLI S, CACCIATORE M, SIMONE NS, CONTINO G, PIRRITANO D, GENTILE M, MASALA A, DELIA A, BULGARELLA A, MAZZA R, RICCI BARBINI V, RAGUSO G, ESPOSITO C, CICALESE V, ALLEGRO R, and PAVONE-MACALUSO M E I MEMBRI DEL GSTU

Published
2005

46. TERAPIA DI II LINEA NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO (HRPC) CON ESTRAMUSTINA FOSFATO ED ETOPOSIDE. STUDIO DI FASE II DEL GSTU

Author

PARRINELLO, Marica, SERRETTA, Vincenzo, GALUFFO, Antonino, ALLEGRO, Rosalinda, MELLONI, Darvinio, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, ALTIERI V, MORGIA G, MAGNO C, PAVONE MACALUSO M. AND MEMBERS OF GRUPPO STUDIO TUMORI UROLOGICI GSTU ABSTRACT COMUNICAZIONE CONGRESSO SOCIETA SICULO CALABRA DI UROLOGIA TRAPANI, PARRINELLO M, SERRETTA V, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, GALUFFO A, ALLEGRO R, ALTIERI V, MORGIA G, MELLONI D, MAGNO C, and PAVONE-MACALUSO M AND MEMBERS OF GRUPPO STUDIO TUMORI UROLOGICI GSTU ABSTRACT COMUNICAZIONE CONGRESSO SOCIETA SICULO-CALABRA DI UROLOGIA TRAPANI

Published
2005

48. ESTRAMUSTINA FOSFATO VS ASSOCIAZIONE A BASSA DOSE DI ESTRAMUSTINA FOSFATO ED ETOPOSIDE NEL CARCINOMA PROSTATICO ORMONOREFRATTARIO. STUDIO RANDOMIZZATO IN FASE II DEL GRUPPO STUDI TUMORI UROLOGICI (GSTU)

Author

SERRETTA, Vincenzo, GALUFFO, Antonino, DISPENSA, Nino, ALLEGRO, Rosalinda, PAVONE, Carlo, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, PAVONE MACALUSO M., SERRETTA V, ALTIERI V, MORGIA G, SIRAGUSA A, MOTTA M, ORESTANO F, NAPOLI M, DE GRANDE G, GALUFFO A, DISPENSA N, ALLEGRO R, PAVONE C, and PAVONE MACALUSO M

Published
2005

Catalog

Books, media, physical & digital resources
See catalog results